Anticoagulation Therapy in Patients with Renal Impairment

Introduction to Anticoagulation Therapy

• The European Society of Cardiology recommends reducing apixaban to 2.5 mg twice daily in patients with impaired renal function if at least two of the following criteria are present: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL (133 μmol/L) 1
• Apixaban has a more favorable profile in renal impairment compared to other direct oral anticoagulants (DOACs) due to its lower renal clearance (27% versus 33% for rivaroxaban and 80% for dabigatran) 1

Dosing Recommendations for Apixaban

• For patients with normal to mild renal impairment (CrCl >50 mL/min), the American Heart Association recommends a dose of 5 mg twice daily 2
• For patients with moderate renal impairment (CrCl 30-50 mL/min), the American Heart Association recommends a dose of 5 mg twice daily unless dose reduction criteria are met 2
• For patients with end-stage renal disease on dialysis, the FDA recommends apixaban 5 mg twice daily with reduction to 2.5 mg twice daily if the patient is ≥80 years of age or body weight is ≤60 kg 2
• The recommended dose of apixaban is 5 mg twice daily for patients with moderate renal impairment (CrCl 15-50 mL/min), unless the patient meets dose reduction criteria, as suggested by the European Society of Cardiology 3

Dosing Recommendations for Rivaroxaban

• A reduced dose of 15mg once daily is recommended for patients with moderate renal impairment (CrCl 15-30 mL/min) 4
• The recommended dose of rivaroxaban is 15 mg once daily for patients with moderate to severe renal impairment (CrCl 15-50 mL/min), which is a 25% dose reduction, as recommended by the European Society of Cardiology 3
• Rivaroxaban should be avoided in patients with end-stage renal disease (CrCl <15 mL/min), as stated by the European Society of Cardiology 5

Dosing Recommendations for Edoxaban

• For patients with CrCl ≤50 mL/min or body weight ≤60 kg, the recommended dose of edoxaban is 30 mg once daily 6

Perioperative Management of Anticoagulation Therapy

• For patients with normal to mild impairment (CrCl >50 mL/min) undergoing low bleeding risk surgery, the International Society on Thrombosis and Haemostasis recommends stopping apixaban 2 days before surgery (skip 2 doses) 7
• For patients with normal to mild impairment (CrCl >50 mL/min) undergoing high bleeding risk surgery, the International Society on Thrombosis and Haemostasis recommends stopping apixaban 3 days before surgery (skip 4 doses) 7

Safety and Efficacy of Anticoagulation Therapy

• Apixaban 5 mg twice daily (with appropriate dose reductions) reduced stroke or systemic embolism by 21% compared with warfarin, combined with a 31% reduction in major bleeding, as demonstrated in the ARISTOTLE trial 1
• Apixaban has a reduced risk of intracranial hemorrhage compared to warfarin 1
• No routine coagulation monitoring is required for apixaban, unlike warfarin 1
• Major bleeding, including intracranial hemorrhage and gastrointestinal bleeding, particularly in older adults, can occur with rivaroxaban use 4

Bleeding Risk Assessment

• The HAS-BLED score should be used to assess bleeding risk, with a score of 3 or higher indicating high bleeding risk, and is calculated as follows:

8, 9

• Patients with high HAS-BLED scores (≥3) should implement bleeding risk reduction strategies, including avoiding NSAIDs and considering proton pump inhibitors for gastroprotection, as recommended by the European Society of Cardiology 10

Stroke Risk Assessment

• The CHA₂DS₂-VASc score is used to assess the risk of stroke in patients with atrial fibrillation, with points assigned for factors such as diabetes, prior TIA, and other conditions, and a total score of 3 or higher indicating a high risk of stroke, and is calculated as follows:

11

• A score ≥2 indicates high stroke risk, according to the American College of Cardiology, and patients with a CHA₂DS₂-VASc score of 3 or higher have a high risk of stroke and require anticoagulation therapy, with a score of 3 indicating a definite need for anticoagulation 12, 11

Patient Education and Monitoring

• Patients and caregivers should be educated on signs of bleeding, importance of adherence to treatment, and potential drug interactions 13, 12
• The American College of Cardiology recommends providing patient education to improve adherence to anticoagulation therapy 13
• Regular monitoring of renal function is essential for patients on DOACs, with the European Society of Cardiology recommending evaluation every 3-6 months 5
• The Cockcroft-Gault equation should be used to calculate creatinine clearance for DOAC dosing decisions, as suggested by the European Society of Cardiology 3

Special Considerations

• DOACs are the preferred option for patients over 90 years old with non-valvular atrial fibrillation, with dose adjustment according to renal function and careful assessment of bleeding risk 13, 12, 11, 14
• Individualized assessment should consider renal function, comorbidities, and risk of falls when evaluating anticoagulation therapy, and a multidisciplinary team approach is recommended to determine the optimal timing for resuming anticoagulation in high bleeding risk situations 13, 12, 11, 14